Home › Compare › NHNCF vs ABBV
NHNCF yields 1.34% · ABBV yields 3.06%● Live data
📍 NHNCF pulled ahead of the other in Year 5
Combined, NHNCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NHNCF + ABBV for your $10,000?
NAVER Corporation, together with its subsidiaries, provides internet and online search portal, and mobile messenger platform services in South Korea, Japan, and internationally. The company offers Naver, a search portal that offers various content topic boards; LINE, a messaging application; Naver Clova, an integrated AI platform; Papago, an automated interpretation application; WHALE, a web browser; Naver Map, a navigation application; Webtoon, a promotion system for mobile comics; SERIES, a paid content platform; SNOW, a camera; BAND, a mobile community platform; NOW, an audio shows to listen to on NAVER app; and NAVER WORKS, which provides features necessary for work, such as Message, Mail, Calendar, and Drive. It also provides IT platforms, BIZ platforms, advertising services, and NAVER SQUARE for business; NAVER Webtoon, NAVER Webnovel, NAVER AudioClip, Series, Premium Contents, NAVER Influencer Center, Creator Advisor, VIBE, NAVER TV, NAVER Post, and Grafolio for creators; and NAVER D2 Startup Factory, DEVIEW, NAVER D2, NAVER Open Source, CLOVA Platform API, NAVER Maps API, papago API, and NAVER login for developers. In addition, NAVER Corporation is involved in the manufacture of cosmetics; electronic financial business; film production and distribution; real estate rental; investment and information business; and character and doll wholesale and retail activities. The company was formerly known as NHN Corporation. NAVER Corporation was founded in 1999 and is headquartered in Seongnam-si, South Korea.
Full NHNCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.